525 related articles for article (PubMed ID: 32702363)
1. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
2. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis.
Muneyyirci-Delale O; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg E; Gillispie V; Hurtado S; Kim JH; Wang A; Wang H; Stewart EA
F S Rep; 2021 Sep; 2(3):338-346. PubMed ID: 34553161
[TBL] [Abstract][Full Text] [Related]
4. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
6. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
[TBL] [Abstract][Full Text] [Related]
7. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
8. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
9. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
[TBL] [Abstract][Full Text] [Related]
10. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
[TBL] [Abstract][Full Text] [Related]
11. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
Muhammad J; Yusof Y; Ahmad I; Norhayati MN
BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
[TBL] [Abstract][Full Text] [Related]
12. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
[TBL] [Abstract][Full Text] [Related]
13. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.
Stewart EA; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg EC; Gillispie-Bell V; Imudia AN; Liu R; Kim JH; Al-Hendy A
J Womens Health (Larchmt); 2022 May; 31(5):698-705. PubMed ID: 34582715
[No Abstract] [Full Text] [Related]
15. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
16. Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial.
Brown E; Kroll R; Li H; Ng J; Pinsky B; Rodriguez JW; Thomas J; Snabes MC
Obstet Gynecol; 2023 Nov; 142(5):1068-1076. PubMed ID: 37769311
[TBL] [Abstract][Full Text] [Related]
17. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
